Güvenir Çelik, E. And Eroğlu, O. 2025. Combined treatment with ruxolitinib and MK-2206 inhibits ERa activity by inhibiting MAPK signaling in BT474 breast cancer cells. JOURNAL OF INVESTIGATIVE MEDICINE , vol.73, no.2 , 218-228.

Güvenir Çelik, E., & Eroğlu, O., (2025). Combined treatment with ruxolitinib and MK-2206 inhibits ERa activity by inhibiting MAPK signaling in BT474 breast cancer cells. JOURNAL OF INVESTIGATIVE MEDICINE , vol.73, no.2, 218-228.

Güvenir Çelik, ESİN, And ONUR EROĞLU. "Combined treatment with ruxolitinib and MK-2206 inhibits ERa activity by inhibiting MAPK signaling in BT474 breast cancer cells," JOURNAL OF INVESTIGATIVE MEDICINE , vol.73, no.2, 218-228, 2025

Güvenir Çelik, ESİN G. And Eroğlu, ONUR. "Combined treatment with ruxolitinib and MK-2206 inhibits ERa activity by inhibiting MAPK signaling in BT474 breast cancer cells." JOURNAL OF INVESTIGATIVE MEDICINE , vol.73, no.2, pp.218-228, 2025

Güvenir Çelik, E. And Eroğlu, O. (2025) . "Combined treatment with ruxolitinib and MK-2206 inhibits ERa activity by inhibiting MAPK signaling in BT474 breast cancer cells." JOURNAL OF INVESTIGATIVE MEDICINE , vol.73, no.2, pp.218-228.

@article{article, author={ESİN GÜVENİR ÇELİK And author={ONUR EROĞLU}, title={Combined treatment with ruxolitinib and MK-2206 inhibits ERa activity by inhibiting MAPK signaling in BT474 breast cancer cells}, journal={JOURNAL OF INVESTIGATIVE MEDICINE}, year=2025, pages={218-228} }